In the seventh interview in the “Portrait of Duchenne” series, our Canadian partners, La Force talked with Ravi Mehta at the Action …
Test with the Potential to More Reliably Screen for Duchenne in Newborns is Developed
Researchers at Cardiff University, in collaboration with biotechnology company PerkinElmer, have created a more reliable test to screen newborn babies …
Test with the Potential to More Reliably Screen for Duchenne in Newborns is DevelopedRead More
Mitobridge’s Potential Treatment for Duchenne Advances into Clinical Development
Mitobridge, Inc., a pioneer in the discovery and development of products that improve mitochondrial function, today announces a key milestone with the …
Mitobridge’s Potential Treatment for Duchenne Advances into Clinical DevelopmentRead More
Worldwide licence for new drug SOMO266 as SOM Biotech expands to the United States
The med-tech biopharmaceutical company, SOM Biotech, has granted a licence agreement with Corino Therapeutics Inc. for its first product SOMO266 for …
Worldwide licence for new drug SOMO266 as SOM Biotech expands to the United StatesRead More
Northern Ireland – ‘My Healthcare Passport’
A new study has started at Queen’s University Belfast. They are looking for young people aged 16-24 with a life-limiting condition and who …
Give your feedback to Summit in their Utrophin modulator patient/family survey
Summit are looking for feedback from caregivers and patients themselves in their commitment to working alongside patients, their families …
Give your feedback to Summit in their Utrophin modulator patient/family surveyRead More
Parity of esteem for people affected by neurological conditions – new report from the Neurological Alliance
The likelihood of having a comorbid mental health condition is higher for neurology patients than for the long-term conditions patient population …
Portrait of Duchenne – edasalonexent
In the fifth interview of the series “Portrait of Duchenne”, our Canadian partners La Fondation La Force talked with Joanne …
Portrait of Duchenne – repurposing existing drugs
In this, the sixth interview in the series Portrait of Duchenne, our Canadian partners La Fondation La Force talked with Steve Winder at the Action …
Sarepta and BioMarin resolve exon skipping patent litigation
Sarepta and BioMarin have executed a license agreement that provides Sarepta Therapeutics with global exclusive rights to BioMarin’s Duchenne muscular …
Sarepta and BioMarin resolve exon skipping patent litigationRead More
Raxone is the first Duchenne drug approved through the Early Access to Medicines Scheme
We are excited to share with the Duchenne community, that Santhera Pharmaceutical’s drug Raxone, is the first Duchenne drug approved via the Early …
Raxone is the first Duchenne drug approved through the Early Access to Medicines SchemeRead More
What Raxone being given approval through the EAMS scheme means for the Duchenne community
Over a number of years we have worked with Santhera Pharmaceuticals and other Duchenne charities in relation to Santhera’s Phase III Clinical Trial …
What Raxone being given approval through the EAMS scheme means for the Duchenne communityRead More
